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When treating sick joints harms lungs, Ixekizumab induced pleural effusion 
 
Abstract 
 
Immunological therapies have provided a multitude of new and effective treatment strategies for 
various disease states. While monoclonal antibody therapy benefits many patients, side effects 
are widely variable. here we present a case of pleural effusion complicating psoriatic arthritis 
treatment. 
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Introduction 
 
Immunological therapies have provided a multitude of new and effective treatment strategies for 
various disease states. While monoclonal antibody therapy benefits many patients, some agents 
have been linked to pulmonary toxicity and pneumonitis. Pleural effusion and pleurisy have not 
previously been described as a side effect of immunological therapy. Here we present a case of 
unilateral, hemorrhagic, lymphocytic pleural effusion in a 50-year-old female caused by 
Ixekizumab, an interleukin-17 (IL 17) inhibitor, treated with corticosteroids resulting in complete 
resolution.   
Case Presentation 
50-year-old female with psoriatic arthritis, hypertension and type II diabetes mellitus presented 
to the emergency department (ED) with shortness of breath. Right lower lobe pneumonia was 
suspected based on chest x-ray. She was discharged on a course of oral levofloxacin. The patient 
presented again to the ED two days later with new, right sided chest pain and worsened dyspnea. 
Upon presentation, the patient reported right sided, pleuritic chest pain and cough productive of 
clear phlegm. She endorsed dyspnea at rest that worsened with exertion. Vital signs were 
significant for hypoxemia with O2 saturation of 88% on room air (RA), tachycardia and 
tachypnea; other vital signs were within reference. Physical examination revealed a female in 
moderate respiratory distress. Auscultation showed decreased air entry bilaterally with dullness 
to percussion at the right lung base. Laboratory workup was significant for leukocytosis of 
17,900 with neutrophilic predominance, elevated ESR and CRP but otherwise was unremarkable 
with the exception of elevated serum creatinine which normalized with gentle hydration (Table 
1). 
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Table 1. Initial Laboratory Results 
 Serum Value Reference 
Range 
WBC 17,900 4,800-10,800 
RBC 5.01 4.2-5.4 million 
Hgb 12.9 g/dL 12-15 g/dL 
Hct 41.5 % 36-47 % 
Platelets 225000 150,000-450000 
Neutrophils 15,900 1,500-7,500 
Lymphocyte 1,100 1,000-4,500 
Monocyte 800 1- 1000 
Eosinophils 0 0-5,000 
Basophils 0 0-200 
Sodium 138 mmol/dL 135-145 mmol/L 
Potassium 4.1 mmol/dL 3.5-5.1 mmol/L 
Chloride 108 mmol/dL 96-108 mmol/L 
Serum 
bicarbonate 
20 mg/dL 21-32 mg/dL 
BUN 11 mg/dL 7-22 mg/dL 
Creatinine 1.4 mg/dL 0.6-1.1 mg/dL 
Glucose 184 mg/dL 70-100 mg/dL 
Procalcitonin < 0.05 0.10 - 0.25 ng/mL 
ESR 48 0 - 26 mm/HR 
CRP 19.4 mg/dL 0 - 0.29 mg/dL 
T - spot Negative Negative 
HIV 1/2 Ab and 
P24 Antigen  
    
 
Negative 
 
Negative 
Respiratory  
Virus Panel 
Negative Negative 
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Chest x-ray showed right lower lobe infiltrate with small pleural effusion (Image 1).  
 
Image 1: Chest x-ray on presentation 
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Empiric treatment with vancomycin and cefepime was started for presumed parapneumonic 
effusion. Over the following 48 hours, the patient's dyspnea continued to worsen. Repeat x-ray 
showed worsening effusion, chest computed tomography (CT) showed normal lung parenchyma 
and significant effusion with no signs suggestive of infection or empyema (Image 2).  
 
Image 2: Initial chest CT scan 
 
Further inquiry into the patient’s recent medical history revealed a recent course of Ixekizumab 
for psoriatic arthritis. The last injection (second one) was two weeks prior to the onset of the 
patient’s dyspnea. 
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Thoracentesis was performed and 750 mL of serosanguinous fluid was removed. Analysis 
revealed a hemorrhagic, exudative effusion with a lymphocytic predominance (Table 2).  
 
Table 2. Pleural Fluid Analysis 
 Pleural Fluid Reference Range 
RBC 59,733 2-1000 mm3 
WBC 1,285 <1000 mm3 
Glucose 73 ~ Plasma 
Lymphocyte 60 2-30% 
Monocyte 5 30-70% 
Eosinophil 1 0% 
LDH 711 <50% plasma LDH 
ADA 8 IU/L <20 IU/L  
Protein 4.5 g/dL 1-2 g/dL 
Albumin 2.1 g/dL 3.4-5.4g/dL 
Gram, Acid 
Fast and 
Fungus 
Stain. 
All Negative No organism 
Acid Fast 
and Fungus 
culture 
Negative after 6 
weeks 
Negative 
 
 
Cytology 
Mixed 
inflammatory 
cells, negative 
for malignancy 
 
 
- 
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Autoimmune and connective tissue disease workup was unremarkable as well as common tumor 
markers (Table 3).  
 
Table 3. Autoimmune Analysis 
 Serum Reference 
Range 
C3 187 90-
180mg/dL 
C4 28 10-
40mg/dL 
P-ANCA <1:20 0-1:20 
C-ANCA <1:20 0-1:20 
Antihistone 
Antibody 
1.2 0-0.9 
IU/mL 
Antinuclear 
Antibody 
>1:80 0-1:80 
Anti-double 
stranded DNA 
<1 0-9 IU/mL 
RNP 0.3 0-0.9 
IU/mL 
Smith <0.2 0-0.9 
IU/mL 
Anti-Chromatin 
Antibody 
<0.2 0-0.9 
IU/mL 
Sjogren’s SSA 
Antibody 
<0.2 0-0.9 
IU/mL 
Sjogren’s SSB 
Antibody 
<0.2 0-0.9 
IU/mL 
Anticentromere B 
Antibody IgG 
<0.2 0-0.9 
IU/mL 
Anti-
Scleroderma-70 
Antibody 
<0.2 0-0.9 
IU/mL 
Anti-Jo-1 
Antibody 
<0.2 0-0.9 
IU/mL 
CA19.9 9 0-35 U/mL 
CA15-3 15.2 0-25 U/mL 
CA 125 11.5 0-35 U/mL 
CEA 1.3 0 -3  ng/mL 
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Microbiologic workup was also unrevealing, yielding negative blood, sputum and pleural fluid 
culture as well as negative gram, acid fast bacilli and fungal stains. Initially, the patient was 
started on non-steroidal anti-inflammatory drugs (NSAID), for which she showed minimal 
response. After pleural fluid analysis, the patient was transitioned to oral steroids with rapid 
resolution of dyspnea and pleuritic chest pain. Patient’s supplemental oxygen requirement 
diminished and functional capacity improved. The patient was discharged on oral prednisone 60 
mg daily with a 6-week tapering dose.  
The patient was seen in pulmonary outpatient clinic four weeks after discharge. Repeat x-ray 
showed complete resolution of pleural effusion (Image 3). 
 
Image 3: Chest CT scan post therapy 
Discussion 
Monoclonal antibody therapy is a new rapidly evolving science showing great promise in the 
management of various disease states, from autoimmune to malignant . Still, little is understood 
about the potential side-effects. 
Classification of T-Cell mediated immunity has expanded beyond the historical description of 
CD4+ and CD8+ T lymphocytes. A subset of CD4+ cell is now defined by the production of 
IL17, the T Helper 17 (Th17 cell). Differentiation of Th17 cells from naïve T-Cells is initiated by 
interleukin 6 (IL 6) and Tissue Growth Factor Beta (TGFᵦ).  Cell populations are expanded, 
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stabilized further by Interleukin-23 (IL 23) through the expression of orphan nuclear receptor 
ROR-γ.1 This system functions in protection of the host organism from the environment, 
specifically in the intestinal mucosa and skin. These cells reside in a preactivated state and 
express an array of sensory receptors that allow them to sense their surroundings.2 
IL 17 is a proinflammatory cytokine secreted by activated Th17 cells. The prototype member of 
this family is designated by the letter A (IL 17A). Five additional subtypes have been identified 
and cloned B, C, D, E and F. The IL 17 signaling system functions in various tissues such as 
articular cartilage, bone, menisci, brain, hematopoietic tissues, kidney, lung, skin and intestine.3 
Signaling through IL 17 Receptor A (IL 17RA) and IL  
17RC, which is highly expressed by epithelial cells, recruits neutrophils and promotes secretion 
of defensin-like factors and maintains tight junctions within the intestinal wall. These factors 
maintain mucosal tissue barrier function.4 Recent studies have suggested a similar system within 
the blood brain barrier in mice.4 Clear understanding has not yet been described in current 
literature.  
Whether a similar system exists in the pleural membrane or direct injury induced by Ixekizumab 
in a way similar to that described in cases of pneumonitis could not be differentiated by this 
report. No confirmatory pleural biopsy was taken and no bronchioalveolar lavage was done, as 
these tests would be invasive and were deferred because the patient responded so promptly to 
steroid therapy and discontinuation of the causal agent.  
Ixekizumab is a humanized IgG4 monoclonal antibody that selectively binds with IL 17A 
cytokine and inhibits its interaction with the IL17 receptor.  Estimated half-life of Ixekizumab is 
thirteen days and time to peak is almost four days, which is consistent with the presentation of 
our patient5 two weeks after the second dose being in second half life of elimination. We 
followed an approach similar to that suggested in immunotherapy associated pneumonitis. After 
careful exclusion of other conditions including infectious causes, we attributed the patient’s  
leukocytosis and neutrophilia to systemic steroids received in the ED and a negative 
procalcitonin level6,7 as well as the high ESR and CRP favoring a noninfectious, inflammatory 
process. Autoimmunity and malignancy were shown to unlikely causes, as shown in Table 3. 
Pleural fluid analysis was more consistent with an inflammatory process. No malignant cells 
were identified on cytology and no micro-organisms where cultured also shown (Table 2). 
Prednisone, 1-2 mg/kg/day was given on a tapering dose by 5-10 mg per week over six weeks 
with complete resolution of effusion.6 In a clinical report, eleven out of forty three patients who 
experienced pneumonitis secondary to checkpoint inhibitor cancer treatments experienced 
recurrence of pneumonitis during drug holding and of steroid therapy. These patients received 
immunotherapy after resolution of pneumonitis, eleven tolerated therapy and three showed 
recurrent pneumonitis of equal severity.8 The decision to restart therapy should be weighted on 
the severity of the disease being treated, as well as the extent of pneumonitis.6 Our patient was 
given the choice and she decided not to resume immunotherapy.  
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Conclusion 
Immune therapy is a rapidly evolving line of treatment modalities which have shown great 
efficacy in treating various disease states and are significantly impacting clinical practice. Still 
little is known about the potential side effects and systemic ramifications associated with their 
use. Here we present the first case of pleural effusion attributed to Ixekizumab. We believe this 
case report will serve to increase practitioner awareness of potentially serious pulmonary 
complications associated with immunotherapy as well as inform them of our approach to 
diagnosis and initial treatment which proved effective. We hope this case report serves to 
highlight potential systemic effects of immunotherapies which are rapidly becoming 
commonplace in clinical practice.   
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